Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM · Entity 11997 | Director · Chief Scientific Officer | March 02, 2023 | March 06, 2023 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | June 09, 2023 | June 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NGM BIOPHARMACEUTICALS INC
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 972,893 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Grant · Acquired 64,000 · Balance 972,893 F1: Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2033-03-01 | Direct | 192,000 |
Reported balance
After 2023-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-02 · Grant · Acquired 192,000 · Balance 192,000 F2: The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2033-03-01 | Direct | 175,000 |
Reported balance
After 2023-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-02 · Grant · Acquired 175,000 · Balance 175,000 F3: 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2: The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
F3: 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.
Tenaya Therapeutics, Inc.
Report date June 09, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2033-06-08 | Direct | 29,532 |
Reported balance
After 2023-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-09 · Grant · Acquired 29,532 · Balance 29,532 F1: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,641 | $1.44 Strike: $1.44 | $26,843.04 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · derivative · entry 14 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,526 Underlying: Common Stock · 173,167 shares Expires 2023-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares subject to the stock option are fully vested. Read SEC document |
| January 09, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 18,641 | $17.95 | $334,607.81 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 9 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,068,443 F7 · kind: The reporting person sold 18,641 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on January 9, 2020. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.74 to $18.385. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 09, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 18,641 | $1.44 | $26,843.04 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 8 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,087,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 71,750 | $0.52 Strike: $0.52 | $37,310.00 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · derivative · entry 13 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,750 shares Expires 2020-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares subject to the stock option are fully vested. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,833 | $1.44 Strike: $1.44 | $2,639.52 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · derivative · entry 12 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,167 Underlying: Common Stock · 175,000 shares Expires 2023-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares subject to the stock option are fully vested. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,201 | $1.44 Strike: $1.44 | $20,449.44 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · derivative · entry 11 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,444 Underlying: Common Stock · 83,645 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares subject to the stock option are fully vested. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 71,750 | $0.52 | $37,310.00 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 7 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,068,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Pursuant to its terms, the option to purchase these shares expires on February 24, 2020, unless earlier exercised. This transaction represents the exercise of the remaining shares under this incentive stock option by the reporting person prior to the expiration date. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 1,833 | $17.98 | $32,956.97 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 6 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,693 F5 · kind: The reporting person sold 1,833 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on January 8, 2020. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.59 to $18.50. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 1,833 | $1.44 | $2,639.52 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 5 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 14,201 | $17.98 | $255,331.14 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 4 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,693 F3 · kind: The reporting person sold 14,021 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on January 8, 2020. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.59 to $18.50. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 14,201 | $1.44 | $20,449.44 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,090 | $1.44 Strike: $1.44 | $23,169.60 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · derivative · entry 10 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,645 Underlying: Common Stock · 99,735 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares subject to the stock option are fully vested. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 16,090 | $18.20 | $292,876.62 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,693 F1 · kind: The reporting person sold 16,090 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on January 7, 2020. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.93 to $18.44. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 19:26 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 16,090 | $1.44 | $23,169.60 |
DisclosureSEC source: 0001209191-20-002910 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (right to buy) · Derivative | 10,986 | $1.44 Strike: $1.44 | $15,819.84 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · derivative · entry 11 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,735 Underlying: Common Stock · 110,721 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 10,986 | $12.26 | $134,693.85 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · nonDerivative · entry 7 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,693 F6 · kind: The reporting person sold 10,986 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on November 1, 2019. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $12.04 to $12.76. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 10,986 | $1.44 | $15,819.84 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · nonDerivative · entry 6 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,007,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (right to buy) · Derivative | 71,750 | $0.52 Strike: $0.52 | $37,310.00 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · derivative · entry 10 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,750 Underlying: Common Stock · 143,500 shares Expires 2020-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (right to buy) · Derivative | 11,403 | $1.44 Strike: $1.44 | $16,420.32 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · derivative · entry 9 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,721 Underlying: Common Stock · 122,124 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 71,750 | $0.52 | $37,310.00 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · nonDerivative · entry 5 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Pursuant to its terms, the option to purchase these shares expires on February 24, 2020, unless earlier exercised. This transaction represents the exercise of a portion of this incentive stock option by the reporting person prior to the expiration date. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 11,403 | $13.29 | $151,524.20 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · nonDerivative · entry 4 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924,943 F3 · kind: The reporting person sold 11,403 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on November 1, 2019. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.52. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 11,403 | $1.44 | $16,420.32 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · nonDerivative · entry 3 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionStock Option (right to buy) · Derivative | 28,376 | $1.44 Strike: $1.44 | $40,861.44 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · derivative · entry 8 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,124 Underlying: Common Stock · 150,500 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | SaleCommon Stock | 28,376 | $12.99 | $368,564.51 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · nonDerivative · entry 2 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924,943 F1 · kind: The reporting person sold 28,376 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on November 1, 2019. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $12.70 to $13.32. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 18:06 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Exercise / conversionCommon Stock | 28,376 | $1.44 | $40,861.44 |
DisclosureSEC source: 0001209191-19-055021 · doc4.xml · nonDerivative · entry 1 CHEN JIN-LONG · CIK 0001642996 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.